Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

94.19 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Corcept (CORT) Q2 Earnings: What To Expect

July 27, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi...

Via StockStory

Topics Artificial Intelligence

Why Corcept (CORT) Stock Is Down Today

July 27, 2026

What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '...

Via StockStory

Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1

July 26, 2026

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Lo...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 22, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗

July 11, 2026

Via Chartmill

Corcept Therapeutics (NASDAQ:CORT) Revenue Miss Leads to Q1 Net Loss, But Guidance Upgrade and Lifyorli Launch Signal Strong Momentum ↗

April 30, 2026

Via Chartmill

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗

July 20, 2026

Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025.

Via The Motley Fool

Topics Regulatory Compliance

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗

July 20, 2026

This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.

Via The Motley Fool

Topics Regulatory Compliance

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗

July 12, 2026

William Guyer's pre-scheduled disposition under a Rule 10b5-1 plan liquidates some direct holdings while retaining 130,000 derivative securities.

Via The Motley Fool

Topics Regulatory Compliance

3 Cash-Heavy Stocks with Questionable Fundamentals

July 07, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Via StockStory

3 High-Flying Stocks We Steer Clear Of

June 30, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...

Via StockStory

3 Unpopular Stocks We Steer Clear Of

June 23, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

June 17, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

June 06, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question

June 01, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

May 29, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

May 27, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

3 Reasons to Sell CORT and 1 Stock to Buy Instead

May 12, 2026

Corcept’s stock price has taken a beating over the past six months, shedding 35% of its value and falling to $50.98 per share. This was partly driven by its ...

Via StockStory

3 High-Flying Stocks We Think Twice About

May 11, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Via StockStory

Corcept (CORT) Q1 2026 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q1 2026 Earnings Transcript

Via The Motley Fool

Corcept (CORT) Q4 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q4 2025 Earnings Transcript

Via The Motley Fool

Corcept (CORT) Q1 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q1 2025 Earnings Transcript

Via The Motley Fool

Corcept (CORT) Q2 2025 Earnings Transcript ↗

May 04, 2026

Corcept (CORT) Q2 2025 Earnings Transcript

Via The Motley Fool

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

May 04, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...

Via StockStory

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

April 30, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...

Via StockStory

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

April 30, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

April 30, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Earnings: What To Look For From CORT

April 28, 2026

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept m...

Via StockStory

Topics Artificial Intelligence

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

April 23, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

April 21, 2026

From Pomerantz LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.